Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma

Leuk Lymphoma. 2007 Feb;48(2):418-20. doi: 10.1080/10428190601059761.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use*
  • DNA, Viral / genetics
  • Herpesvirus 4, Human / genetics*
  • Herpesvirus 4, Human / isolation & purification
  • Humans
  • Immunoblastic Lymphadenopathy / complications
  • Immunoblastic Lymphadenopathy / therapy
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, B-Cell / etiology
  • Lymphoma, B-Cell / virology
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / etiology
  • Lymphoma, Large B-Cell, Diffuse / virology
  • Lymphoma, T-Cell, Peripheral / complications*
  • Lymphoma, T-Cell, Peripheral / therapy
  • Male
  • Middle Aged
  • Neoplasms, Second Primary / drug therapy
  • Neoplasms, Second Primary / etiology
  • Neoplasms, Second Primary / virology
  • Peripheral Blood Stem Cell Transplantation / adverse effects*
  • Remission Induction
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • DNA, Viral
  • Rituximab